Â鶹Æƽâ°æ est fier d\u2019annoncer l\u2019initiation d\u2019une collaboration de recherche avec le professeur Julian Walters de l\u2019Imperial Coll\u00e8ge London. Le principal objectif de ces recherches est d\u2019\u00e9valuer le potentiel th\u00e9rapeutique de l\u2019utilisation de la mol\u00e9cule EYP001 (agoniste de FXR). Les pr\u00e9l\u00e8vements d\u2019il\u00e9ons humains obtenus chez des sujets sains seront expos\u00e9s \u00e0 des concentrations croissantes de l\u2019agoniste de FXR d\u00e9velopp\u00e9 par Â鶹Æƽâ°æ.<\/p>\n","protected":false},"excerpt":{"rendered":"
Â鶹Æƽâ°æ est fier d\u2019annoncer l\u2019initiation d\u2019une collaboration de recherche avec le professeur Julian Walters de l\u2019Imperial Coll\u00e8ge London. Le principal objectif de ces recherches est d\u2019\u00e9valuer le potentiel th\u00e9rapeutique de l\u2019utilisation de la mol\u00e9cule EYP001 (agoniste de FXR). Les pr\u00e9l\u00e8vements d\u2019il\u00e9ons humains obtenus chez des sujets sains seront expos\u00e9s \u00e0 des concentrations croissantes de l\u2019agoniste de FXR d\u00e9velopp\u00e9 par Â鶹Æƽâ°æ.<\/p>\n
Lire la suite »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-1797","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"Br\u00e8ves<\/a>","rttpg_excerpt":"Â鶹Æƽâ°æ est fier d\u2019annoncer l\u2019initiation d\u2019une collaboration de recherche avec le professeur Julian Walters de l\u2019Imperial Coll\u00e8ge London. Le principal objectif de ces recherches est d\u2019\u00e9valuer le potentiel th\u00e9rapeutique de l\u2019utilisation de la mol\u00e9cule EYP001 (agoniste de FXR). Les pr\u00e9l\u00e8vements d\u2019il\u00e9ons humains obtenus chez des sujets sains seront expos\u00e9s \u00e0 des concentrations croissantes de…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1797"}],"version-history":[{"count":10,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1797\/revisions"}],"predecessor-version":[{"id":2846,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1797\/revisions\/2846"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}